The U.S. Supreme Court reversed a lower-court decision that generics-makers can't sue makers of brand-name drugs to force them to limit the scope of patent description with the FDA. The high court ruled in favor of Caraco Pharmaceutical Laboratories, which aims to launch a generic version of Prandin, a diabetes drug by Novo Nordisk.

Related Summaries